Repligen Corporation (RGEN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Repligen Corporation (RGEN) reported a robust Q2 2025, achieving 17% ex-COVID organic growth and 20% orders growth. This strong performance, building on a solid Q1, resulted in mid-teens top-line growth for the first half of the year, positioning the company for a strong full-year 2025 across its entire portfolio, as highlighted by CEO Olivier Loeillot.

Analysis

Repligen Corporation (RGEN) has demonstrated a significant operational rebound, reporting 17% ex-COVID organic growth in Q2 2025. This performance, highlighted by CEO Olivier Loeillot, builds upon a strong Q1 and results in mid-teens top-line growth for the first half of the year. Critically, order growth has accelerated to 20% over the same period, providing strong forward-looking visibility and suggesting sustained demand. Management expressed high confidence, noting that the robust performance across the entire product portfolio is setting the company up for a strong full-year 2025, signaling a clear recovery and positive fundamental momentum.

Key Decisions for Investors

• Given the reported 17% ex-COVID organic growth and accelerating 20% order growth, investors should view these metrics as confirmation of a robust operational recovery, supporting a bullish outlook on near-term revenue.
• The CEO's confident full-year 2025 guidance, underpinned by broad-based portfolio strength, suggests that current long positions could be held or augmented, as the positive momentum appears sustainable.
• Investors should closely monitor upcoming earnings for sustained mid-teens growth and strong order book conversion to validate management's optimistic forward-looking statements.